Gliofocus – Phase 3 Study of Niraparib for Glioblastoma
  • August 8, 2024
The Gliofocus Study is a global, open-label, randomized Phase 3 clinical trial sponsored by the Ivy Brain Tumor Center that will compare the efficacy of niraparib, a PARP1/2-selective inhibitor, versus temozolomide in adult patients with newly diagnosed MGMT unmethylated glioblastoma. 
Learn More
BDTX-1535 FOR RECURRENT HIGH-GRADE GLIOMA
  • January 8, 2024
The Ivy Brain Tumor Center is conducting a Phase 0/1 clinical trial to evaluate BDTX-1535, an experimental drug intended to block a key growth signal in patients with recurrent high-grade glioma, driven by EGFR (Epidermal Growth Factor Receptor) genetic aberrations.
Learn More
ONC201 IN NEWLY DIAGNOSED H3 K27M-MUTANT DIFFUSE GLIOMA
  • August 4, 2023
The Ivy Brain Tumor Center at Barrow Neurological Institute, a nonprofit translational research program, is conducting a Phase 3 study to evaluate ONC201 in patients with newly diagnosed H3 K27M-mutant diffuse glioma.
Learn More
Temsirolimus in Recurrent High-Grade Glioma
  • January 17, 2023
A Phase 0 dose-escalation study using superselective intra-arterial cerebral infusion of temsirolimus for the treatment of recurrent high-grade glioma. 
Learn More
AZD1390 FOR GRADE 4 GLIOMA
  • March 15, 2022
A Phase 0/1b clinical trial to evaluate AZD1390 in patients with recurrent and newly diagnosed WHO grade 4 glioma.
Learn More
SONODYNAMIC THERAPY IN RECURRENT HIGH-GRADE GLIOMA
  • March 5, 2022
A Phase 0 research study of intravenous Aminolevulinic Acid Hydrochloride (ALA) and MR-guided focused ultrasound device (MRgFUS) in recurrent high-grade glioma patients.
Learn More